Karo Bio AB
Records under this name other than patents Karo Bio AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,367,665 | Estrogen receptor ligands Formerly held Lapsed on the fee record Ended Feb 5, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 5, 2025 | From the USPTO record |
| US 8,921,402 | Substituted pyrazoles as estrogen receptor ligands Lapsed on the fee record Ended Dec 30, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 30, 2022 | From the USPTO record |
| US 8,895,282 | Use of a substance for manufacturing of a medicament for treatment of common cold Lapsed on the fee record Ended Nov 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 25, 2022 | From the USPTO record |
| US 6,800,605 | Aniline-Derived Ligands for the Thyroid Receptor Term ended Term ended Sep 22, 2022 · High confidence | Term ended | Term ended Sep 22, 2022 | High confidence |
| US 8,710,243 | Estrogen receptor ligands Lapsed on the fee record Ended Apr 29, 2022 · From the USPTO record | Lapsed on the fee record | Ended Apr 29, 2022 | From the USPTO record |
| US 8,653,072 | Estrogen receptor ligands Formerly held Lapsed on the fee record Ended Feb 18, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 18, 2022 | From the USPTO record |
| US 8,653,112 | Substituted pyrazoles as estrogen receptor ligands Lapsed on the fee record Ended Feb 18, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 18, 2022 | From the USPTO record |
| US 9,586,891 | Estrogen receptor ligands Formerly held Lapsed on the fee record Ended Mar 7, 2021 · From the USPTO record | Lapsed on the fee record | Ended Mar 7, 2021 | From the USPTO record |
| US 7,342,127 | Substituted Anilide Ligands for the Thyroid Receptor Lapsed on the fee record Ended Mar 11, 2020 · High confidence | Lapsed on the fee record | Ended Mar 11, 2020 | High confidence |
| US 6,228,990 | Estrogen receptor ligands Term ended Term ended Feb 12, 2019 · From the USPTO record | Term ended | Term ended Feb 12, 2019 | From the USPTO record |